• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Sezary Syndrome - Pipeline Review, H1 2013 - Product Image

Sezary Syndrome - Pipeline Review, H1 2013

  • ID: 2557581
  • May 2013
  • 29 pages
  • Global Markets Direct

Sezary Syndrome – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sezary Syndrome.
- A review of the Sezary Syndrome products under development by companies and universities/research institutes based READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Sezary Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Sezary Syndrome
Sezary Syndrome Therapeutics under Development by Companies
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Sezary Syndrome Therapeutics – Products under Development by Companies
Companies Involved in Sezary Syndrome Therapeutics Development
Shionogi & Co., Ltd.
Innate Pharma SA
Spectrum Pharmaceuticals, Inc.
Sezary Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IPH-41 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
[pralatrexate] + [bexarotene] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon gamma-1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sezary Syndrome Therapeutics – Drug Profile Updates
Sezary Syndrome Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Sezary Syndrome, H1 2013
Products under Development for Sezary Syndrome – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Shionogi & Co., Ltd., H1 2013
Innate Pharma SA, H1 2013
Spectrum Pharmaceuticals, Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Sezary Syndrome Therapeutics – Drug Profile Updates
Sezary Syndrome Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Sezary Syndrome, H1 2013
Products under Development for Sezary Syndrome – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 21

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos